Toll-like Receptor 2 Gene Polymorphism, Serum Cytokines and Susceptibility to Disease Severity or Treatment Response of Pulmonary Tuberculosis
NCT00772408 · Status: COMPLETED · Type: OBSERVATIONAL · Enrollment: 300
Last updated 2013-02-28
Summary
Infection with Mycobacterium tuberculosis remains at epidemic levels globally. Innate and adaptive immune responses evolve as protective mechanisms against mycobacterial infection in humans. Toll-like receptors (TLRs) are transmembrane proteins characterized by an extracellular leucine-rich domain that participates in ligand recognition and an intracellular tail. TLRs are the first defense system to detect potential pathogens, initiate immune responses and form the crucial link between innate and adaptive immune systems. Stimulation of TLR initiates a signaling cascade that involves a number of proteins, such as MyD88 and IL-1 receptor-associated kinase. This signal cascade leads to NF-κB activation, which induce the secretion of pro-inflammatory cytokines.
TLR2 is a family of TLR family and has been reported to be the principle mediator of macrophage activation in response to mycobacterium. Growing amounts of data suggest that the ability of certain individuals to respond properly to TLR ligands may be impaired by single nucleotide polymorphisms (SNPs) within TLR genes, resulting in an altered susceptibility to, or course of, infectious disease. The genetic polymorphism of TLR2 (arginine to glutamine substitution at residue 753 (Arg753Gln)) has been associated with a negative influence on TLR2 function, which may, in turn, determine the innate host response to mycobacteria. In addition, another polymorphism (Arg677Trp) of the TLR2 was reported to be associated with susceptibility to tuberculosis in Tunisian patients. Moreover, in Mycobacterium leprosy patients with TLR2 mutation (Arg677Trp), production of IL-2, IL-12, IFN-gamma, and TNF-alpha by M. leprae-stimulated peripheral blood mononuclear cell were decreased compared with that in groups with wild-type TLR2.
To date, there have been no studies of the association of SNPs of TLR2 with cytokine profiles and clinical outcomes on M. tuberculosis. We hypothesize that polymorphisms in the TLR2 are associated with :
1. increased prevalence of active pulmonary TB infection,
2. altered levels of pro-inflammatory and anti-inflammatory cytokines in serum,
3. clinical outcomes and presentations. We thus design a prospective case-control study to test this hypothesis. The frequency of TLR2 polymorphisms in both pulmonary TB patients and healthy controls will be determined by polymerase chain reaction-restriction fragment length polymorphism. Serial serum levels of IL-12, IFN-γ, and IL-10 in pulmonary TB patients with or without TLR2 polymorphisms will be measured by enzyme linked immunosorbent assay. Relationships between TLR2 polymorphisms and serum cytokines dynamics or clinical outcomes will be analyzed.
Conditions
- Pulmonary Tuberculosis
- Genetic Variants of Host
- Immune Response of Host
Sponsors & Collaborators
-
Chang Gung Memorial Hospital
lead OTHER
Principal Investigators
-
Meng-Chih Lin, MD · Chang Gung Memorial Hospital
Eligibility
- Min Age
- 20 Years
- Max Age
- 90 Years
- Sex
- ALL
- Healthy Volunteers
- Yes
Timeline & Regulatory
- Start
- 2006-08-31
- Primary Completion
- 2009-11-30
- Completion
- 2009-11-30
Countries
- Taiwan
More Related Trials
-
Autoantibodies Against Specific Cytokines in Adults With Severe Mycobacterial Infection
NCT01628744 ·Status: UNKNOWN
-
Evaluation of Immune Cell Markers in Diagnosis of Tuberculosis
NCT04148053 ·Status: UNKNOWN
-
Expression of Tuberculosis in the Lung
NCT00201253 ·Status: COMPLETED
-
The Molecular Mechanism and the Role of NRAMP 1gene on Tuberculosis in Taiwan Aboriginal Tribes Population
NCT00266383 ·Status: COMPLETED
-
Diagnostic Utility of Mycobacterium Tuberculosis Cell-free DNA
NCT06439810 ·Status: RECRUITING
-
Immune Responses to Mycobacterium Tuberculosis (Mtb) in People With Latent Tuberculosis Infection With or Without Concomitant Helminth Infection
NCT02225158 ·Status: TERMINATED
-
The Role of a Mycobacterium Growth Inhibition Assay to Quantify Host Immune Control of M. Tuberculosis
NCT06580639 ·Status: RECRUITING
-
Respiratory Microbiota and Immune Response in CVID
NCT06173128 ·Status: COMPLETED
-
Lung Innate Immunity and Microbiome After Tuberculosis Exposure
NCT06526689 ·Status: RECRUITING
-
The Role of Apoptosis Associated Markers in Pathogenesis of Pulmonary Tuberculosis
NCT01676155 ·Status: UNKNOWN
-
Clinical Research on Comprehensive Treatment of Tuberculosis With Malignant Solid Tumor
NCT03551795 ·Status: COMPLETED ·Phase: PHASE1/PHASE2
-
Immune Response to Mycobacterium Tuberculosis Infection
NCT00257907 ·Status: COMPLETED
-
Quantitative Measurement of Plasma and Urine MTB Cell-free DNA Level
NCT07170735 ·Status: RECRUITING
-
Surveillance and Follow-up for Latent Tuberculosis Infection and Observation of the Effect of Prophylactic Latent Tuberculosis Treatment in Patients With Severe Chronic Kidney Disease or Receiving Long-term Dialysis
NCT01685086 ·Status: UNKNOWN
-
Paradoxical Reactions in Non Immuno-compromized Patients With Extrapulmonary Tuberculosis
NCT01252992 ·Status: COMPLETED
-
TBP Survey Among Respiratory Physicians
NCT06390969 ·Status: COMPLETED
-
MTB cfDNA Levels in TBP
NCT05397730 ·Status: COMPLETED
-
Latent Tuberculosis Infection in Renal Transplant Recipients
NCT00682045 ·Status: COMPLETED
-
Oral Vitamin D and Toll Like Receptor in Spondylitis Tuberculosis
NCT05376189 ·Status: UNKNOWN ·Phase: PHASE2/PHASE3
-
Surveillance and Follow-up for Latent Tuberculosis Infection and Risk of Developing Active Tuberculosis in Patients Receiving Long-term Dialysis
NCT01311999 ·Status: COMPLETED
-
Doxycycline in Human Pulmonary Tuberculosis
NCT02774993 ·Status: COMPLETED ·Phase: PHASE2
-
Training Protocol on the Natural History of Tuberculosis
NCT01212003 ·Status: RECRUITING
-
Evaluation of Non-Inferiority of Two Fast Follower Nucleic Acid Amplification Tests
NCT02252198 ·Status: COMPLETED
-
ESAT6/CFP10 Skin Testing for TB Infection in Rheumatologic Patients
NCT06796647 ·Status: RECRUITING
-
Plasma MTB cfDNA Before Bronchoscopy
NCT07230457 ·Status: NOT_YET_RECRUITING